Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Design and interim safety analysis of GeparX trial

Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany

Design and interim safety analysis of GeparX trial ( Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany )

Subcutaneous daratumumab shows benefit in patients with relapsed or refractory...

Dr Ajai Chari - Mount Sinai Hospital, New York, USA

$Subcutaneous daratumumab shows benefit in patients with relapsed or refractory multiple myeloma ( Dr Ajai Chari - Mount Sinai Hospital, New York, USA )$

Avelumab in combinations for lung cancer and update from ALEX study

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Avelumab in combinations for lung cancer and update from ALEX study ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

Daratumumab in combination with carfilzomib and dexamethasone for relapsed...

Dr Ajai Chari - Mount Sinai Hospital, New York, USA

Daratumumab in combination with carfilzomib and dexamethasone for relapsed multiple myeloma ( Dr Ajai Chari - Mount Sinai Hospital, New York, USA )

Phase III results of PROSPECT study for metastatic, castration-resistant...

Dr James Gulley - Center for Cancer Research, Washington, USA

Phase III results of PROSPECT study for metastatic, castration-resistant prostate cancer ( Dr James Gulley - Center for Cancer Research, Washington, USA )

Pancreatic survival improved with trial chemotherapy regimen after surgery

Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Pancreatic survival improved with trial chemotherapy regimen after surgery ( Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

Aspirin combined with acid-reducing medicine offers moderate benefits in...

Prof Janusz Jankowski - Royal College of Surgeons in Ireland, Dublin, Republic...

Aspirin combined with acid-reducing medicine offers moderate benefits in patients with Barrett’s oesophagus ( Prof Janusz Jankowski - Royal College of Surgeons in Ireland, Dublin, Republic of Ireland )

Comment: Aspirin with acid-reducing medicine reduces chance of oesophageal...

Dr Andrew Epstein and Prof Richard Schilsky

Comment: Aspirin with acid-reducing medicine reduces chance of oesophageal cancer in high risk individuals ( Dr Andrew Epstein and Prof Richard Schilsky )

Aspirin with acid-reducing medicine reduces chance of oesophageal cancer in...

Prof Janusz Jankowski - Royal College of Surgeons in Ireland, Dublin, Republic...

Aspirin with acid-reducing medicine reduces chance of oesophageal cancer in high risk individuals ( Prof Janusz Jankowski - Royal College of Surgeons in Ireland, Dublin, Republic of Ireland )

ASCO 2018: Latest developments in non-metastatic and metastatic castration...

Dr Neal Shore, Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik

ASCO 2018: Latest developments in non-metastatic and metastatic castration-resistant prostate cancer ( Dr Neal Shore, Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik )

ASCO 2018: Integrating genomic data throughout treatment for prostate cancer

Prof Kurt Miller and Prof Bertrand Tombal

ASCO 2018: Integrating genomic data throughout treatment for prostate cancer ( Prof Kurt Miller and Prof Bertrand Tombal )

Zoptarelin no better than doxarubicin for second-line advanced endometrial...

Dr David Miller - The University of Texas Southwestern Medical Center

Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer ( Dr David Miller - The University of Texas Southwestern Medical Center )

More from ecancer